Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fesoterodine 4mg Clear all
Completed Phase 3 Interventional Results available

Fesoterodine "add-on" Male Overactive Bladder Study

NCT00546637
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years and older · Male only
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2011 · Synced Nov 9, 2026, 10:03 AM EST
Completed Phase 4 Interventional Results available

A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency

NCT00911937
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
112
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Nov 9, 2026, 10:03 AM EST
Terminated Phase 4 Interventional Results available

Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate

NCT01605617
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine fumarate, Placebo, Percutaneous Tibial Nerve Stimulation (PTNS)
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Nov 9, 2026, 10:03 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder

NCT01925456
View directory record Official record
Conditions
Overactive Bladder
Interventions
Toviaz
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Nov 9, 2026, 10:03 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects

NCT01161472
View directory record Official record
Conditions
Healthy
Interventions
4mg fesoterodine, 8mg fesoterodine, alprazolam 1mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Nov 9, 2026, 10:03 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia

NCT00605319
View directory record Official record
Conditions
Bladder Outlet Obstruction
Interventions
Toviaz (Fesoterodine)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 99 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Nov 9, 2026, 10:03 AM EST
Completed Phase 4 Interventional

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

NCT01661166
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Fesoterodine, Placebo oral tablet
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
30 Years to 90 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Nov 9, 2026, 10:03 AM EST
Completed Phase 4 Interventional Results available

A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

NCT01302067
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine 8mg, Fesoterodine 4mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
165
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 130 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Nov 9, 2026, 10:03 AM EST
Completed Phase 3 Interventional Results available

Fesoterodine Flexible Dose Study

NCT00536484
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
95
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Nov 9, 2026, 10:03 AM EST
Not listed Phase 4 Interventional Accepts healthy volunteers

Premarin Versus Toviaz for Treatment of Overactive Bladder

NCT01613170
View directory record Official record
Conditions
Overactive Bladder
Interventions
Toviaz, Premarin, Placebo cream
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
30 Years to 100 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Nov 9, 2026, 10:03 AM EST